Sionna Therapeutics said its PreciSION CF Phase 2a study of SION-719 as an add-on to Trikafta failed to meet its key activity endpoint. The company will discontinue development of SION-719 in cystic fibrosis as standard-of-care add-on therapy, a negative clinical outcome that may pressure expectations for its CF pipeline.
Sionna Therapeutics said its PreciSION CF Phase 2a study of SION-719 as an add-on to Trikafta failed to meet its key activity endpoint. The company will discontinue development of SION-719 in cystic fibrosis as standard-of-care add-on therapy, a negative clinical outcome that may pressure expectations for its CF pipeline.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
